Association of polymorphisms of the xeroderma pigmentosum complementation group F gene with increased glioma risk

• DOI: 10.4238/2014.may.16.7
• Publication Date: 2014-05-16T19:35:43Z
• Authors: W.K. Zhou; L.Y. Huang; L. Hui; Z.W. Wang; B.Z. Jin; X.L. Zhao; X.Z. Zhang; J.X. Wang; J.C. Wang; R.Z. Wang
• Keywords: Adult; Male; Glioma; Middle Aged; Polymorphism, Single Nucleotide; 3. Good health; DNA-Binding Proteins; 03 medical and health sciences; 0302 clinical medicine; Risk Factors; Case-Control Studies; Humans; Female; Genetic Predisposition to Disease; Alleles; Genetic Association Studies; Aged

We aimed to investigate the role of 4 single nucleotide polymorphisms of the xeroderma pigmentosum complementation group F (XPF) gene (rs3136038, rs1799798, rs1800067, and rs2276466) in glioma, and the roles of gene-gene interactions in the risk of developing this type of cancer. We collected samples from 225 glioma cases and 262 controls and genotyped the rs3136038, rs1799798, rs1800067, and rs2276466 polymorphisms using a 384-well plate format with the Sequenom MassARRAY platform. Individuals carrying the rs1800067 GG genotype were more likely to have an increased risk of glioma when compared with carriers of the A/A genotype in a co-dominant model, with an odds ratio (OR) [95% confidence interval (CI)] of 2.85 (1.14-7.76). However, we did not find an association with increased risk of glioma for the polymorphisms rs3136038, rs1799798, and rs2276466 in XPF. The combination genotype of the rs1800067 G allele and the rs2276466 G allele was associated with a moderate risk of glioma (OR = 1.71, 95%CI = 1.02-2.87). Our study suggests that the rs1800067 genetic variant of XPF functions in the development of glioma.